Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Neuroendocrine effects of apomorphine in chronic schizophrenic patients under long-term neuroleptic therapy and after drug withdrawal: Relations to psychopathology and tardive dyskinesia (1984)
    Springer
    Psychopharmacology 84 (1984), S. 436-440 
    Details
    ISSN: 1432-2072
    Keywords: Chronic schizophrenics ; Long-term neuroleptic therapy ; Neuroleptic withdrawal ; Growth Hormone ; Prolactin ; Psychopathology ; Tardive Dyskinesia
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract The sensitivity of the dopaminergic hypothalamic pituitary system, as indicated by growth hormone (GH) release after apomorphine (0.5 mg SC), was studied in 11 chronic schizophrenic in-patients under long-term neuroleptic (NL) therapy and after 12 and 30 days' drug withdrawal. GH peak levels after a 12-day drug-free period were significantly elevated (13.1±12 ng/ml) as compared to NL therapy (4.6±6.1 ng/ml). Controls showed a significant higher mean peak GH response (13.6±10 ng/ml) compared to chronic schizophrenic patients under long-term NL therapy. The GH response of patients with symptoms of tardive dyskinesia (TD) did not differ significantly from that of patients without signs of TD. The prolactin (PRL) serum levels under long-term NL treatment were within the normal range in male schizophrenics but decreased significantly after 12 days' drug withdrawal. The data presented indicate a reduced sensitivity of the hypothalamic-pituitary dopamine receptors under long-term NL therapy. The significant increase in GH response on day 12 probably corresponds to a readjustment from a mostly blunted GH response under NL therapy back to stimulated levels of normal controls. No supersensitivity of the pituitary dopamine recpetors could be detected.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00555228
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Photochemical donor pretreatment in clinical kidney transplantation —Preliminary report (1987)
    Springer
    Urological research 15 (1987), S. 211-213 
    Details
    ISSN: 1434-0879
    Keywords: Kidney transplantation ; Donor pretreatment ; PUVA ; Ultraviolet irradiation
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Extended experimental experience with the efficiacy of pretreating the kidney donor and the allograft by means of photochemotherapy (photosensitizer+UVA irradiation=PUVA) was adopted in clinical kidney transplantation. In a preliminary unrandomized study similar patient populations were treated by generally uniform methods. Thirty-three PUVA-pretreated kidneys (group A) were compared with the experience regarding 26 nonpretreated kidney allografts (group B). The number of rejection episodes was significantly lower in the first 3 months in group A (p〈 0.05 vs group B) and fewer grafts failed because of irreversible rejection (2 vs 5). Furthermore, in group A the rate of infectious complications was lower (18% vs 34%). The cumulative allograft survival at 3 months was improved from 65% in group B to 81% in group A and at 12 months from 65% 76%, respectively. These differences were not significant. Therefore, our preliminary clinical experience with a photochemical donor pretreatment is encouraging and further use in a randomized study seems to be necessary.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00262102
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...